SCHEMBL23488271

SCHEMBL23488271

COc1cc(C(=O)OC[C@H]2OC[C@H](O)[C@@H](O)[C@H]2O)cc(Cl)c1OC(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MAPT P10636 1/20 0.43
PTPN1 P18031 2/20 0.39
XDH P47989 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
NR1I2 O75469 1/20 0.37
CHRM2 P08172 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADRA2B P18089 1/20 0.37
SLC6A4 P31645 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
CHRNA4 P43681 1/20 0.37
SLC6A3 Q01959 1/20 0.37
PDE4D Q08499 1/20 0.37
KCNH2 Q12809 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488432 0.85 ALDH1A1 (0.41) ALDH1A1MAPTPTPN1XDHPDE4D
SCHEMBL23488272 0.85 TDP1 (0.43) ALDH1A1MAPTPTPN1XDHTDP1
SCHEMBL23488431 0.85 TDP1 (0.43) ALDH1A1MAPTPTPN1XDHTDP1
SCHEMBL23488436 0.84 KMT2A (0.49) ALDH1A1MAPTXDHTDP1KMT2A
SCHEMBL23488124 0.84 TDP1 (0.49) ALDH1A1MAPTPTPN1XDHTDP1
SCHEMBL23488410 0.81 XDH (0.48) ALDH1A1MAPTPTPN1XDHTDP1
SCHEMBL23488411 0.79 XDH (0.47) PTPN1XDHTDP1
SCHEMBL23488418 0.77 KMT2A (0.48) ALDH1A1MAPTTDP1KMT2ASMN1; SMN2
SCHEMBL23488156 0.75 NPC1 (0.53) ALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL24137802 0.74 TDP1 (0.46) ALDH1A1MAPTPTPN1XDHTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 ALDH1A1 1627/4885MAPT 3481/4885PTPN1 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.